English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background Hepatitis C virus (HCV) is a major cause of chronic liver disease and requirement for liver transplantation. Shared acquisition risk factors mean that HIV co-infection is common. Co-infection has been shown to lead to faster progression of liver fibrosis. Combination therapy for HCV with pegylated interferon-alpha and ribavirin (pegIFN/ RBV) results in comparable sustained virological response (SVR) rates for HIV/HCV co-infected patients vs. HCV mono-infected patients. Monitoring early viral kinetics, specifically baseline HCV viral load and week 4 HCV PCR can allow tailoring of treatment duration for specific patients and give prognostic information regarding primary treatment success.

Continuing evidence to support the role of early kinetic monitoring in predicting sustained viral response for HIV/HCV co-infected patients